国际泌尿系统杂志
國際泌尿繫統雜誌
국제비뇨계통잡지
INTERNATIONAL JOURNAL OF UROLOGY AND NEPHROLOGY
2012年
6期
771-773
,共3页
膀胱肿瘤%癌,移行性细胞%半胱氨酸蛋白酶类
膀胱腫瘤%癌,移行性細胞%半胱氨痠蛋白酶類
방광종류%암,이행성세포%반광안산단백매류
Bladder Neoplasms%Carcinoma,Transitional Cell%Cysteine Proteinases
目的 探讨凋亡抑制基因survivin在膀胱移行细胞癌中的表达及意义.方法 膀胱移行细胞癌组87例,20例正常正常膀胱黏膜作为对照,采用免疫组织化学方法检测survivin蛋白表达,然后分析survivin蛋白在膀胱癌组织中的表达情况,以及随着不同临床分期和病理分级表达的变化.结果 所有膀胱 癌患者平均年龄56.1岁,其中男性患者48例.免疫组织化学分析表明,survivin蛋白表达在细胞的细胞核.膀胱癌组织中survivin表达明显高于正常对照组.随着临床分期的进展,survivin表达上升.结论 survivin 在膀胱移行细胞癌的生物学行为中起重要作用,survivin与膀胱移行细胞癌的恶性进展有关.
目的 探討凋亡抑製基因survivin在膀胱移行細胞癌中的錶達及意義.方法 膀胱移行細胞癌組87例,20例正常正常膀胱黏膜作為對照,採用免疫組織化學方法檢測survivin蛋白錶達,然後分析survivin蛋白在膀胱癌組織中的錶達情況,以及隨著不同臨床分期和病理分級錶達的變化.結果 所有膀胱 癌患者平均年齡56.1歲,其中男性患者48例.免疫組織化學分析錶明,survivin蛋白錶達在細胞的細胞覈.膀胱癌組織中survivin錶達明顯高于正常對照組.隨著臨床分期的進展,survivin錶達上升.結論 survivin 在膀胱移行細胞癌的生物學行為中起重要作用,survivin與膀胱移行細胞癌的噁性進展有關.
목적 탐토조망억제기인survivin재방광이행세포암중적표체급의의.방법 방광이행세포암조87례,20례정상정상방광점막작위대조,채용면역조직화학방법검측survivin단백표체,연후분석survivin단백재방광암조직중적표체정황,이급수착불동림상분기화병리분급표체적변화.결과 소유방광 암환자평균년령56.1세,기중남성환자48례.면역조직화학분석표명,survivin단백표체재세포적세포핵.방광암조직중survivin표체명현고우정상대조조.수착림상분기적진전,survivin표체상승.결론 survivin 재방광이행세포암적생물학행위중기중요작용,survivin여방광이행세포암적악성진전유관.
Objectives To investigate the apoptosis gene survivin expression in bladder transitional cell carcinoma and its significance.Methods Bladder Transitional cell carcinoma 87 cases,20 cases of normal,normal bladder mucosa served as controls,using immunohistochemistry to detect expression of survivin protein,and then analysis of survivin protein expression in bladder cancer,as well as the different clinical stage and histological grading expression changes.Results The average age of all patients with bladder cancer is 56.1 years old,48 cases were male patients.Immunohistochemical analysis of survivin protein expression in the cell nucleus.Survivin expression in bladder cancer tissue was significantly higher than the normal control group.With the progress of clinical stage,survivin expression increased.Conclusions Survivin plays an important role in the biological behavior and malignant progression of bladder transitional cell carcinoma.